Why do patients with antiphospholipid syndrome bleed? A clinical paradox
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
Although worldwide-known criteria of antiphospholipid syndrome include thrombotic and obstetric events, a moderate number of patients manifest with bleeding episodes during course of the disease, which is typically attributed to the long-term anticoagulation. However, these haemorrhagic manifestations sometimes are part of pathophysiological changes that might occur secondary to the disease that involves endothelial activation, platelets dysfunction and blood clot factors misfunction. Recognizing these mechanisms of bleeding is crucial not only due to the need of treatment change or adding, but also because of changes in the disease' prognosis. In this review, we attempted to explain those complications, from its mechanism to a treatment approach, in order for physicians to be able to recognize patients with antiphospholipid syndrome and haemorrhagic manifestations, and to understand that, beyond over-anticoagulation, there are some other mechanisms that can trigger this complication and thus carry out a better diagnostic and therapeutic approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis - 34(2023), 5 vom: 01. Juli, Seite 257-262 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fuentes-Lacouture, María Cynthia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Antiphospholipid |
|---|
| Anmerkungen: |
Date Completed 12.07.2023 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/MBC.0000000000001083 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355217449 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355217449 | ||
| 003 | DE-627 | ||
| 005 | 20240314234420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MBC.0000000000001083 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM355217449 | ||
| 035 | |a (NLM)37017010 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fuentes-Lacouture, María Cynthia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Why do patients with antiphospholipid syndrome bleed? A clinical paradox |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2023 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Although worldwide-known criteria of antiphospholipid syndrome include thrombotic and obstetric events, a moderate number of patients manifest with bleeding episodes during course of the disease, which is typically attributed to the long-term anticoagulation. However, these haemorrhagic manifestations sometimes are part of pathophysiological changes that might occur secondary to the disease that involves endothelial activation, platelets dysfunction and blood clot factors misfunction. Recognizing these mechanisms of bleeding is crucial not only due to the need of treatment change or adding, but also because of changes in the disease' prognosis. In this review, we attempted to explain those complications, from its mechanism to a treatment approach, in order for physicians to be able to recognize patients with antiphospholipid syndrome and haemorrhagic manifestations, and to understand that, beyond over-anticoagulation, there are some other mechanisms that can trigger this complication and thus carry out a better diagnostic and therapeutic approach | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Gómez, Lizeth Bustamante |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Nicolás |e verfasserin |4 aut | |
| 700 | 1 | |a Arteaga-Unigarro, Carlos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis |d 1992 |g 34(2023), 5 vom: 01. Juli, Seite 257-262 |w (DE-627)NLM012606456 |x 1473-5733 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:5 |g day:01 |g month:07 |g pages:257-262 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MBC.0000000000001083 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 5 |b 01 |c 07 |h 257-262 | ||